Adaptive SBRT boost yields 63% two-year locoregional control in stage III NSCLC

In 51 patients with unresectable stage III NSCLC, an adaptive SBRT boost achieved 62.8% two-year locoregional control, with hemoptysis raising safety concerns.

KEY POINTS

  • This prospective, single-center, single-arm cohort from Erciyes University, Turkey, evaluated response-adaptive SBRT boost following concurrent chemoradiotherapy in patients with unresectable stage III NSCLC. Between February 2021 and October 2023, 54 patients were enrolled and 51 completed the protocol, including 31.4% with stage IIIC disease and 52.9% with initially ultracentral tumors. Median age was 63 years, and median follow-up was 26 months. No patient received consolidation durvalumab because reimbursement was unavailable during the study period.
  • Initial chemoradiotherapy delivered 50 Gy in 25 fractions with concurrent weekly carboplatin AUC 2 and paclitaxel 50 mg/m², followed by a new 4DCT-based treatment plan. Residual primary disease received 30 Gy in five SBRT fractions, while persistent involved nodes received an additional 10 Gy in five fractions. Adaptive PTV expansions were 3 mm for the primary tumor and 5 mm for nodal disease, with daily CBCT guidance. The median interval between CRT and boost initiation was 13 days.
  • Adaptive replanning substantially reduced the volume exposed to the highest dose. Median primary tumor volume decreased from 73.6 to 24.6 cm³, corresponding to a 55.4% reduction (p<0.01). Median pathological nodal volume decreased by 33.3%. Following dose accumulation using deformable image registration, the median cumulative dose to the residual primary PTV was 94.9 Gy EQD2, corresponding to BED10 of 113.8 Gy. The number of ultracentral primary tumors decreased from 27 to 20 between the initial and adaptive treatment phases.
  • Two-year locoregional control was 62.8%, with overall survival of 61.5%. One-year locoregional control reached 76.0%, while one-, two-, and three-year overall survival was 75.8%, 61.5%, and 57.7%, respectively. Median progression-free survival was 13 months, and median distant metastasis-free survival was 16 months. Among 28 patients with progression, 21 (41.2% of the cohort) developed distant metastases, compared with 17 (33.3%) experiencing locoregional progression, demonstrating that distant failure remained the dominant limitation.
  • Higher cumulative primary-tumor dose and lower post-treatment metabolic activity were associated with better locoregional control. A cumulative dose below 94.77 Gy EQD2 was associated with increased locoregional failure (adjusted HR 5.86, 95% CI 1.78–19.28; p<0.01), while three-month locoregional SUVmax ≥4.55 was also unfavorable (HR 5.04, 95% CI 1.51–16.75; p<0.01). Both thresholds were derived from ROC analysis within the same cohort and are exploratory rather than validated treatment-planning or response-assessment cutoffs.
  • Pulmonary and esophageal toxicity were clinically relevant. Grade 2 radiation pneumonitis occurred in 23.5% and grade 3–4 pneumonitis in 7.8%, including three grade 4 events (5.9%). Grade 3 esophagitis occurred in one patient (2.0%), whose esophageal dose exceeded predefined constraints. Grade 3–4 neutropenia occurred in 7.8%. Without a conventional-CRT control group, the additional contribution of SBRT boost to these toxicities cannot be determined.
  • Hemoptysis was the most important safety signal. Five patients (9.8%) developed hemoptysis before death, including all three patients with documented pre-existing hemoptysis and two patients without previous bleeding. Three of the five also developed locoregional recurrence, making treatment attribution uncertain. In two patients, the proximal bronchial tree D0.33cm³ exceeded 94.8 Gy EQD2, although no significant dose association was demonstrated across the cohort (p=0.67). Interpretation is further limited by the exclusion of three enrolled patients who did not complete the protocol, the lack of a comparator, and the absence of consolidation immunotherapy.

CLINICAL TAKEAWAY

Response-adaptive SBRT boost after concurrent chemoradiotherapy achieved measurable locoregional control in selected patients with unresectable stage III NSCLC, including bulky and initially ultracentral disease, but distant progression remained common. The observed pneumonitis and hemoptysis, particularly among patients with previous bleeding or central airway involvement, warrant substantial caution. This single-arm experience does not establish a survival benefit or justify replacing contemporary chemoradiotherapy followed by indicated consolidation immunotherapy.

SOURCE

International Journal of Radiation Oncology, Biology, Physics

Browse more research Suggest a correction